A5021806116- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Bladder and Urothelial Cancer Treatments
- Cancer Cells and Metastasis
- Colorectal Cancer Screening and Detection
- Colorectal Cancer Treatments and Studies
- Molecular Biology Techniques and Applications
- RNA modifications and cancer
- Lung Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Epigenetics and DNA Methylation
- MicroRNA in disease regulation
- Liver Disease and Transplantation
- Organ Transplantation Techniques and Outcomes
- Sarcoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Liver Disease Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Neutropenia and Cancer Infections
Natera (United States)
2019-2024
Aarhus University Hospital
2018
University of Nebraska Medical Center
1997
Sensitive methods for risk stratification, monitoring therapeutic efficacy, and early relapse detection may have a major impact on treatment decisions patient management stage III colorectal cancer patients. Beyond assessing the predictive power of postoperative ctDNA detection, we explored added benefits serial analysis: adjuvant chemotherapy (ACT) growth rates.We recruited 168 patients with treated curative intent at Danish Spanish hospitals between 2014 2019. To quantify in plasma samples...
PURPOSE More than 50% of patients with stage IV colorectal cancer (metastatic [mCRC]) relapse postresection. The efficacy postoperative systemic treatment is limited in this setting. Thus, these would greatly benefit from the use a reliable prognostic biomarker, such as circulating tumor DNA (ctDNA) to identify minimal or molecular residual disease (MRD). PATIENTS AND METHODS We analyzed cohort 112 mCRC who had undergone metastatic resection curative intent part PREDATOR clinical trial....
Circulating tumor DNA (ctDNA) analysis may improve early-stage breast cancer treatment via non-invasive burden assessment. To investigate subtype-specific differences in the clinical significance and biology of ctDNA shedding, we perform serial personalized hormone receptor (HR)-positive/HER2-negative triple-negative (TNBC) patients receiving neoadjuvant chemotherapy (NAC) I-SPY2 trial. positivity rates before, during, after NAC are higher TNBC than HR-positive/HER2-negative patients. Early...
Abstract Purpose: To investigate whether circulating tumor DNA (ctDNA) assessment in patients with muscle-invasive bladder cancer predicts treatment response and provides early detection of metastatic disease. Experimental Design: We present full follow-up results (median follow-up: 68 months) from a previously described cohort neoadjuvant chemotherapy (NAC)-treated who underwent longitudinal ctDNA testing (712 plasma samples). In addition, we performed evaluation 153 samples collected...
Abstract Background In early‐stage non–small cell lung cancer (NSCLC), recurrence is frequently observed. Circulating tumor DNA (ctDNA) has emerged as a noninvasive tool to risk stratify patients for after curative intent therapy. This study aimed with NSCLC via personalized, tumor‐informed multiplex polymerase chain reaction (mPCR) next‐generation sequencing assay. Methods retrospective cohort included stage I–III NSCLC. Recruited received standard‐of‐care management (surgical resection or...
PURPOSE Here, we report the sensitivity of a personalized, tumor-informed circulating tumor DNA (ctDNA) assay (Signatera) for detection molecular relapse during long-term follow-up patients with breast cancer. METHODS A total 156 primary cancer were monitored clinically up to 12 years after surgery and adjuvant chemotherapy. Semiannual blood samples prospectively collected, analyzed retrospectively detect residual disease by ultradeep sequencing using ctDNA assays, developed from whole-exome...
Surgery is the only curative therapeutic option for resectable extrahepatic cholangiocarcinoma (eCCA), but recurrence common, and prognosis poor. There an unmet clinical need improved decision-making regarding adjuvant chemotherapy (ACT). Here we evaluated usefulness of monitoring longitudinal circulating tumor DNA (ctDNA) minimal residual disease (MRD) in patients STAMP trial, which compares efficacy capecitabine (CAP) versus gemcitabine plus cisplatin (GemCis).
11 Background: Timely detection of recurrence, as well identification patients at high risk recurrence after surgery and completion adjuvant therapy, are major challenges in the treatment colorectal cancer (CRC). Postsurgical circulating tumor DNA (ctDNA) analysis is a promising tool for with minimal residual disease (MRD) recurrence. The objective this prospective, multicenter study was to determine whether serial postsurgical ctDNA could identify provide an assessment therapy efficacy...
102 Background: Numerous studies have shown the clinical utility of ctDNA, a non-invasive biomarker to detect MRD and stratify CRC patients who are more likely relapse. We present an analysis detection in from prospective multicentre UK study, were monitored pre- post-surgery before adjuvant chemotherapy (ACT). Methods: The study recruited diagnosed with stage II-III (n=122), including subset rectal underwent tri-modality treatment (TMT). All had their primary tumor resected 56% (68/122)...
4009 Background: The clinical utility of tracking circulating tumor DNA (ctDNA) as a non-invasive biomarker for detecting minimal residual disease (MRD) and stratifying patients based on their risk developing relapse has been well established in colorectal cancer (CRC). This study evaluates the detection longitudinal monitoring ctDNA CRC pre- post-operatively, during after adjuvant chemotherapy (ACT). Methods: prospective, multicenter cohort recruited (n = 193) diagnosed with resected stage...
562 Background: Up to 30% of patients with breast cancer relapse after primary treatment. There are no sensitive or reliable tests monitor these and detect distant metastases before overt recurrence. Here, we demonstrate the use personalized circulating tumour DNA (ctDNA) profiling performed postoperatively, postadjuvantly, serially for detection recurrence in cancer. Methods: Patients (n=188) were recruited following surgery adjuvant therapy followed-up up 10 years semi-annual blood...
Abstract Background: In the I-SPY 2 TRIAL, addition of P to standard NAC resulted in more than doubling pathologic complete response (pCR) rates for both hormone receptor-positive (HR+)/HER2- and triple-negative (TN) early breast cancer (EBC) patients (pts) compared only (Nanda et al, JAMA Oncol, 2020). At 3 years, distant recurrence-free survival (DRFS) pts with pCR following NAC+P was >95%. We hypothesized that ctDNA can serve as a predictive biomarker treated NAC. Methods: A...
3540 Background: Challenges in the postoperative management of stage III colorectal cancer include: 1) selection high-risk patients for adjuvant chemotherapy (ACT), 2) lack markers to assess ACT efficacy, 3) assessment recurrence risk after ACT, and 4) guide treatment decisions e.g. additional therapy or intensified surveillance. Circulating tumor DNA (ctDNA) is a promising marker with potential mitigate challenges. Here we used serial ctDNA measurements correlation between detection:...
9564 Background: Our exploratory study aimed to understand the association between presence of ctDNA after definitive surgical resection and RFS in pts with stage III melanoma treated adjuvant immunotherapy. Methods: This included 92 resected enrolled a phase 3 trial (NCT02506153) that evaluated efficacy pembrolizumab compared interferon alfa-2b or ipilimumab IIIA(N2a)-IV melanoma. Personalized, tumor-informed assays (Signatera) were run on banked plasma samples (median: 3.8 mL) collected at...
Abstract Early detection of disease recurrence has shown to improve survival in patients with early-stage colorectal cancer (CRC) (Pita-Fernandez et al., 2015). Detection circulating tumor DNA (ctDNA) postoperatively stage II colon provides direct evidence residual and identifies at high risk (Tie 2016). Previous studies have performed ctDNA analysis monitor burden CRC using small gene panel sequencing or digital droplet PCR (ddPCR) assays detect specific variants 2016, Reinert Building upon...
Abstract Background: Triple negative breast cancer (TNBC) is the most aggressive subtype, even in early stages. Evidence of molecular residual disease (MRD), after treatment with curative intent (surgery, chemotherapy), predating macroscopic recurrence can provide rationale for therapeutic intervention, potentially improving patient outcomes. Longitudinal evaluation circulating tumor DNA (ctDNA) emerging as a promising marker efficacy and recurrence, validated to pre-date by radiological...
e12523 Background: Inflammatory breast cancer (IBC) is a rare, aggressive form of and despite multimodal treatment approach, it associated with early recurrence poor prognosis. There need for sensitive reliable biomarkers therapy response monitoring prediction disease progression. The prognostic predictive role circulating tumor DNA (ctDNA) as biomarker molecular residual (MRD) following surgery has been established several types. In this study, we provide evidence that tumor-informed ctDNA...
<p>Biological characteristics of ctDNA shedding tumors</p>
<p>Longitudinal ctDNA data for NAC-treated patient cohort</p>
<div>AbstractPurpose:<p>To investigate whether circulating tumor DNA (ctDNA) assessment in patients with muscle-invasive bladder cancer predicts treatment response and provides early detection of metastatic disease.</p>Experimental Design:<p>We present full follow-up results (median follow-up: 68 months) from a previously described cohort neoadjuvant chemotherapy (NAC)-treated who underwent longitudinal ctDNA testing (712 plasma samples). In addition, we performed...
Abstract Background: The detection of circulating tumor DNA (ctDNA) may serve as an early predictor response and recurrence. In this study, we used a tumor-informed ctDNA test to monitor clinical outcomes in patients with high-risk hormone receptor-positive HER2-negative (HR+HER2-) tumors who received neoadjuvant chemotherapy (NAC) on the I-SPY 2 trial (NCT01042379). Methods: We collected blood samples at pretreatment, during (at 3 12 weeks after initiation paclitaxel-based treatment or...